Clinical Trial Detail

NCT ID NCT03179436
Title Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

non-small cell lung carcinoma

lung small cell carcinoma

Therapies

MK-1308 + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST